CN13 - Impact of AI clinical trial program on screening, matching, and enrollment of patients over 6 months

Background

The Tempus AI TIME program is a comprehensive clinical trial solution consisting of a diverse study portfolio, an algorithmic AI enabled trial matching platform (TApp), and rapid activation process that partners with clinical sites to increase trial access and facilitate study enrollment.

Methods

The TApp utilized patient data, trial eligibility criteria, and natural language processing models for AI matching to TIME studies. TApp searches were triggered by changes to patient data or trial criteria. Potential TApp matches were reviewed by a Tempus nurse and sites notified of confirmed matches. Trials were activated “just in time” (JIT) if an eligible patient was ready, or prospectively before the first patient was identified. Activations used TIME’s standardized operational methods including a pre-negotiated rate card, clinical trial agreement (CTA), and central IRB. Data collected included TIME network population size, TApp searches, patient matches, activation time, and consents across all TIME sites during a 6-month period.

Results

Between 7/1/23 - 12/31/23 the TIME network included 94 sites (840,523 patients) and 74 trials. The TApp performed 280,661,946 searches resulting in 847,689 potential trial matches. Based on site feasibility and lookback criteria, TIME nurses screened 24,533 patients with 4,443 matches for interventional trials. These matches resulted in 71 activations (activation time of 14.4 days for JIT, 38.8 days for prospective) and 189 consents. Table: CN13

Conclusions

The Tempus AI TIME program facilitated large-scale patient screening and matching for clinical trials, improving patient access and enrollment with an average of 1+ consents per day over 6 months. AI-enhanced patient matching and rapid trial activation should be leveraged to optimize trial success.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Tempus AI, Inc.

Funding

Tempus AI, Inc.

Disclosure

D. Shepard: Financial Interests, Personal, Advisory Board: Deciphera, Aadi, Sanofi, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Springworks; Financial Interests, Institutional, Local PI: Novartis, Pfizer, NucMito, Kinnate, Aadi, Conjupro, Prelude, Seagen, Cogent, Deciphera, Inhibrx, Compugen. S. Mallahan: Financial Interests, Personal, Full or part-time Employment: Tempus AI. C. Osterman: Financial Interests, Personal, Full or part-time Employment: Tempus. D. Skelly: Financial Interests, Personal, Full or part-time Employment: Tempus AI; Financial Interests, Personal, Stocks/Shares: Tempus AI. E. Patnaude: Financial Interests, Personal, Full or part-time Employment: Tempus AI; Financial Interests, Personal, Stocks/Shares (restricted stock units): Tempus AI. B.H. O’Neil: Financial Interests, Personal, Invited Speaker: AstraZeneca. A. Rao: Financial Interests, Personal, Full or part-time Employment: Tempus AI. A. Zarzour: Financial Interests, Personal, Advisory Board: Mirati, DSI. M.G. Goldstein: Financial Interests, Personal, Other, Consultant paid hourly as: Tempus; Non-Financial Interests, Principal Investigator, Multiple Clinical trials: Center for Cancer and Blood Disorders; Non-Financial Interests, Other, Board Member: Maryland DC Society of Clinical Oncology. A.G. Franzen: Financial Interests, Personal, Stocks/Shares: Tempus AI; Financial Interests, Personal, Full or part-time Employment: Tempus AI. E. Cohen: Financial Interests, Personal, Other, Consulting: Eisai, Merck, MSD, Nectin Tx, Pangea Therapeutics, Roche, Adagene, Astellas, Cidara, Genmab, Gilboa, iTeos, Eli Lilly, Novartis, Nykode, PCI Biotech, Replimune, Soteria, Viracta; Financial Interests, Personal, Other, DSMB: Kura; Financial Interests, Personal, Other, BOD: Akamis Bio; Financial Interests, Personal, Stocks/Shares: Kinnate Biophama, Primmune Therapeutics. M. Cooney: Financial Interests, Personal, Full or part-time Employment: Tempus AI; Financial Interests, Personal, Stocks/Shares: Tempus AI. All other authors have declared no conflicts of interest.